dr. garassino on immunotherapy in egfr-mutated lung cancer
Published 6 years ago • 440 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
1:36
dr. garassino discusses recent pivotal immunotherapy findings in nsclc
-
0:56
dr. garon on potential for immunotherapy in egfr nsclc
-
1:30
dr. garassino on erlotinib/ramucirumab versus osimertinib in egfr nsclc
-
1:42
dr. bazhenova on sequential use of immunotherapy and egfr tkis in lung cancer
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
9:41
immunotherapy with antiangiogenics in nsclc
-
4:07
chemotherapy with i-o therapy in egfr- or alk-mutated nsclc
-
2:05
dr. garassino discusses promising findings with osimertinib for patients with nsclc and brain mets
-
9:16
changing treatment paradigm for braf-mutant nsclc
-
1:36
dr. garassino on increased pfs with ramucirumab combo for nsclc
-
3:24
sequencing of therapies in egfr-mutant nsclc
-
1:34
dr. garassino on the pacific trial for nsclc
-
1:53
dr. garassino discusses pros with durvalumab by pd-l1 expression in stage iii nsclc
-
2:20
dr. liu on resistance mechanisms in egfr-mutant lung cancer
-
1:31
dr. garassino on qol findings from the flaura study in nsclc
-
1:58
dr. bazhenova on sequencing beyond progression in egfr-mutant nsclc
-
1:11
dr. sequist on rationale for tatton trial in egfr-mutant lung cancer
-
1:27
dr. wakelee discusses egfr tkis in lung cancer
-
1:31
dr. gold on the future of osimertinib in lung cancer